116 related articles for article (PubMed ID: 37249585)
21. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
22. Impact of individual and neighborhood factors on socioeconomic disparities in localized and advanced prostate cancer risk.
DeRouen MC; Schupp CW; Yang J; Koo J; Hertz A; Shariff-Marco S; Cockburn M; Nelson DO; Ingles SA; Cheng I; John EM; Gomez SL
Cancer Causes Control; 2018 Oct; 29(10):951-966. PubMed ID: 30136012
[TBL] [Abstract][Full Text] [Related]
23. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
24. Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.
Feng X; Zhou CK; Clish CB; Wilson KM; Pernar CH; Dickerman BA; Loda M; Finn SP; Penney KL; Schmidt DR; Vander Heiden MG; Giovannucci EL; Ebot EM; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):1000-1008. PubMed ID: 33627383
[TBL] [Abstract][Full Text] [Related]
25. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J; Cai PY; Alnajar H; Bhinder B; Park K; Ye H; Beg S; Sailer V; Siddiqui J; Blattner-Johnson M; Croyle JA; Noorzad Z; Calagua C; MacDonald TY; Axcrona U; Bogaard M; Axcrona K; Scherr DS; Sanda MG; Johannessen B; Chinnaiyan AM; Elemento O; Skotheim RI; Rubin MA; Barbieri CE; Mosquera JM
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35050902
[TBL] [Abstract][Full Text] [Related]
26. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
[TBL] [Abstract][Full Text] [Related]
27. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men.
Beyene DA; Naab TJ; Kanarek NF; Apprey V; Esnakula A; Khan FA; Blackman MR; Brown CA; Hudson TS
Prostate; 2018 Aug; 78(11):801-811. PubMed ID: 29682763
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance and EZH2, ERG and SPINK1 protein expression in pure and mixed ductal adenocarcinoma of the prostate.
Patil PA; McKenney JK; Reynolds JP; Przybycin CG; Magi-Galluzzi C
Histol Histopathol; 2019 Apr; 34(4):381-390. PubMed ID: 30246858
[TBL] [Abstract][Full Text] [Related]
30. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
[TBL] [Abstract][Full Text] [Related]
31. Association of Neighborhood Deprivation With Prostate Cancer and Immune Markers in African American and European American Men.
Pichardo MS; Minas TZ; Pichardo CM; Bailey-Whyte M; Tang W; Dorsey TH; Wooten W; Ryan BM; Loffredo CA; Ambs S
JAMA Netw Open; 2023 Jan; 6(1):e2251745. PubMed ID: 36662526
[TBL] [Abstract][Full Text] [Related]
32. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
[TBL] [Abstract][Full Text] [Related]
33. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
[TBL] [Abstract][Full Text] [Related]
34. Use of empiric methods to inform prostate cancer health disparities: Comparison of neighborhood-wide association study "hits" in black and white men.
Lynch SM; Sorice K; Tagai EK; Handorf EA
Cancer; 2020 Jan; 126(9):1949-1957. PubMed ID: 32012234
[TBL] [Abstract][Full Text] [Related]
35. The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer.
Pan X; Zhang X; Gong J; Tan J; Yin X; Tang Q; Shu K; Shen P; Zeng H; Chen N
Prostate; 2016 Jun; 76(9):823-33. PubMed ID: 27159572
[TBL] [Abstract][Full Text] [Related]
36. Molecular alterations in prostate cancer and association with MRI features.
Lee D; Fontugne J; Gumpeni N; Park K; MacDonald TY; Robinson BD; Sboner A; Rubin MA; Mosquera JM; Barbieri CE
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):430-435. PubMed ID: 28762374
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
38. The association between neighborhood greenness and incidence of lethal prostate cancer: A prospective cohort study.
Iyer HS; James P; Valeri L; Hart JE; Pernar CH; Mucci LA; Holmes MD; Laden F; Rebbeck TR
Environ Epidemiol; 2020 Apr; 4(2):e091. PubMed ID: 32656487
[TBL] [Abstract][Full Text] [Related]
39. Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers.
Cheng E; Soulos PR; Irwin ML; Cespedes Feliciano EM; Presley CJ; Fuchs CS; Meyerhardt JA; Gross CP
JAMA Netw Open; 2021 Dec; 4(12):e2139593. PubMed ID: 34919133
[TBL] [Abstract][Full Text] [Related]
40. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
